Tribute Pharmaceuticals, Pozen deal

Pozen is acquiring fellow specialty pharma Tribute in a deal the companies say is valued at $146 million. The combined company will be renamed Aralez Pharmaceuticals plc and located in Ireland and will trade on NASDAQ or the TSX. Pozen shareholders will own about 66% of the newco, with Tribute shareholders owning the remainder. The deal is expected to be completed in 4Q15. Tribute had 2014 revenues of C$16.9 million ($14.6 million), and Pozen revenues of $32.4 million for the same period. ...